Radioactive beads aim to shrink inoperable liver tumors
NCT ID NCT07391839
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a single injection of MDN-001, which contains tiny radioactive beads (Yttrium-90), in 40 people with liver cancer that cannot be removed by surgery. The goal is to see if the treatment is safe and can shrink tumors, slow disease progression, and improve quality of life. Participants will be monitored for side effects and tumor response for at least 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Yttrium-90 microspheres (radioactive beads delivered via injection)
What this could lead to
If successful, this could provide a new treatment option to shrink liver tumors in patients who cannot have surgery, potentially extending survival.
What could go wrong
This is an early phase 1/2 trial with only 40 participants, so safety and effectiveness are not yet proven. Radioactive microspheres can cause side effects like liver damage or radiation sickness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anhui Provincial Hospital
RECRUITINGHefei, Anhui, 230001, China
-
Henan Cancer Hospital
RECRUITINGHenan, Zhengzhou, 450008, China
-
Shandong Cancer Hospital
RECRUITINGJinan, Shandong, 250117, China
-
The First Affiliated Hospital of Fujian Medical University
RECRUITINGFuzhou, Fujian, 350005, China
-
The First Affiliated Hospital of Jinan University
RECRUITINGGuangzhou, Guangdong, 510630, China
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, 310022, China
-
Zhongda Hospital
RECRUITINGNanjing, Jiangsu, 210009, China
-
Zhongshan hospital
RECRUITINGShanghai, 200032, China